B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

To evaluate the protective effect of B-type natriuretic peptide (BNP) on CIN in patients with heart failure undergoing PCI.

Serum creatinine (SCr) levels were measured to evaluate the protective effect of rhBNP on renal function.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In the prospective, placebo-controlled, randomized trial, 149 consecutive acute myocardial infarction (AMI) patients with heart failure undergoing primary PCI received recombinant human BNP (rhBNP) or placebo from the time of admission to 24 h after PCI.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Some participants received a placebo instead of BNP (Nesiritide), giving a reference point.

Estimated glomerular filtration rate (eGFR) was calculated by the simplified modification of diet in renal disease study equation.

What Was Measured

The subject headings attached to it are Angioplasty, Contrast Media, Creatinine, Glomerular Filtration Rate, Heart Failure, Kidney Diseases and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of BNP (Nesiritide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Acta radiologica (Stockholm, Sweden : 1987)), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.